CoChat
Sign Up
Cited by 101Growth Hormone and Insulin-like Growth FactorsDiabetes, Cardiovascular Risks, and LipoproteinsLipid metabolism and disorders

Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics

Krag, Morten B., Gormsen, Lars C., Guo, ZengKui, Christiansen, Jens S., Jensen, Michael D., Nielsen, Søren, Jørgensen, Jens O. L.·2007·American Journal of Physiology-Endocrinology and Metabolism
DOI 10.1152/ajpendo.00374.2006
Open this paper in CoChat — free account

Abstract

The ability of growth hormone (GH) to stimulate lipolysis and cause insulin resistance in skeletal muscle may be causally linked, but the mechanisms remain obscure. We investigated the impact of GH on the turnover of FFA and VLDL-TG, intramuscular triglyceride content (IMTG), and insulin sensitivity (euglycemic clamp) in nine healthy men in a randomized double-blind placebo-controlled crossover study after 8 days treatment with (A) Placebo+Placebo, (B) GH (2 mg daily)+Placebo, and (C) GH (2 mg daily)+Acipimox (250 mgx3 daily). In the basal state, GH (B) increased FFA levels (P<0.05), palmitate turnover (P<0.05), and lipid oxidation (P=0.05), but VLDL-TG kinetics were unaffected. Administration of acipimox (C) suppressed basal lipolysis but did not influence VLDL-TG kinetics. In the basal state, IMTG content increased after GH (B; P=0.03). Insulin resistance was induced by GH irrespective of concomitant acipimox (P<0.001). The turnover of FFA and VLDL-TG was suppressed by hyperinsulinemia during placebo and GH, whereas coadministration of acipimox induced a rebound increase FFA turnover and VLDL-TG clearance. We conclude that these results show that GH-induced insulin resistance is associated with increased IMTG and unaltered VLDL-TG kinetics; we hypothesize that fat oxidation in muscle tissue is an important primary effect of GH and that circulating FFA rather than VLDL-TG constitute the major source for this process; and the role of IMTG in the development of GH-induced insulin resistance merits future research.

Integrity signals

Registry

Crossref · 10.1152/ajpendo.00374.2006

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Growth hormone is unlikely to be a factor in the associations between sleep and insulin secretion, as GH increases insulin resistance rather than insulin secretion.

    “Although growth hormone (GH) secretion occurs largely during the N3 sleep (23), GH is unlikely to be a factor in the associations, as GH increases insulin resistance (24) rather than insulin secretion.”

    From Sleep architecture and glucose and insulin homeostasis in obese adolescents (2011) · cites this paper as [24]

Cites

Flagged first, then by citations

1 of the 51 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Krag, M. B., Gormsen, L. C., Guo, Z., Christiansen, J. S., Jensen, M. D., Nielsen, S., & Jørgensen, J. O. L.
Affiliations
  • Aarhus University Hospital (DK)
  • Aarhus University (DK)
ORCID
Venue
American Journal of Physiology-Endocrinology and Metabolism
Publisher
American Physiological Society
Published
2007-03
Volume
292
Issue
3
Pages
E920-E927
ISSN
  • 0193-1849 (ISSN-L)
  • 1522-1555
DOI
10.1152/ajpendo.00374.2006
OpenAlex
W2135012391
Cited by
101
References
51
Citations by year
2026: 2 · 2025: 4 · 2024: 2 · 2023: 7 · 2022: 2 · 2021: 5 · 2020: 2 · 2019: 7 · 2018: 3 · 2017: 1 · 2016: 1 · 2015: 6 · 2014: 8 · 2013: 7 · 2012: 9
FWCI
5.91
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Physiology-Endocrinology and Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
growth hormone, insulin resistance, intramyocellular triglyceride, free fatty acid turnover, acipimox, lipolysis, hyperinsulinemic-euglycemic clamp, fat oxidation
MeSH terms
Adult, Body Weight, Calorimetry, Indirect, Fatty Acids, Nonesterified, Glucose, Humans, Insulin Resistance, Insulin-Like Growth Factor I, Lipoproteins, VLDL, Male, Placebos, Growth Hormone, Triglycerides, Muscle Fibers, Skeletal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review